UNC Eshelman School of Pharmacy
Gauri Rao has not added Biography.
If you are Gauri Rao and would like to personalize this page please email our Author Liaison for assistance.
Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii.
International journal of antimicrobial agents Sep, 2016 | Pubmed ID: 27449542
Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies.
The Journal of antimicrobial chemotherapy 11, 2016 | Pubmed ID: 27494922
Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae.
Antimicrobial agents and chemotherapy 02, 2017 | Pubmed ID: 27872078
Multi-scale model of drug induced adaptive resistance of Gram-negative bacteria to polymyxin B.
PloS one , 2017 | Pubmed ID: 28334005
Critical Need for Clarity in Polymyxin B Dosing.
Antimicrobial agents and chemotherapy 05, 2017 | Pubmed ID: 28438796
Assessment of Combined Polymyxin B and Minocycline Therapy against Klebsiella pneumoniae Carbapenemase (KPC)-Producing K. pneumoniae.
Antimicrobial agents and chemotherapy 07, 2017 | Pubmed ID: 28438930
Triple combination antibiotic therapy for carbapenemase-producing Klebsiella pneumoniae: a systematic review.
Annals of clinical microbiology and antimicrobials Nov, 2017 | Pubmed ID: 29178957
Effect of polymyxin B-containing regimens on renal function for the treatment of carbapenem-resistant Enterobacteriacea mediastinitis.
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases Jan - Feb, 2018 | Pubmed ID: 29182906
Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for Injection) against KPC-Producing Klebsiella pneumoniae.
Antimicrobial agents and chemotherapy 02, 2018 | Pubmed ID: 29203494
Assessment and modelling of antibacterial combination regimens.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases Jul, 2018 | Pubmed ID: 29269090
Validation of a Model Predicting Anti-infective Lung Penetration in the Epithelial Lining Fluid of Humans.
Pharmaceutical research Jan, 2018 | Pubmed ID: 29368211
Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm.
Antimicrobial agents and chemotherapy 07, 2018 | Pubmed ID: 29760144
Comparison of the composition and in vitro activity of polymyxin B products.
International journal of antimicrobial agents Sep, 2018 | Pubmed ID: 29807163
Impact of Antibiotic Resistance on Treatment of Pneumococcal Disease in Ethiopia: An Agent-Based Modeling Simulation.
The American journal of tropical medicine and hygiene 11, 2019 | Pubmed ID: 31516111
Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing.
Journal of pharmaceutical sciences 12, 2020 | Pubmed ID: 32891630
A mechanism-based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID-19 treatment in humans.
CPT: pharmacometrics & systems pharmacology 02, 2021 | Pubmed ID: 33296558
Reapproaching Old Treatments: Considerations for PK/PD Studies on Phage Therapy for Bacterial Respiratory Infections.
Clinical pharmacology and therapeutics 06, 2021 | Pubmed ID: 33615463
The Complex Roadmap to Infectious Disease Innovation: The Intersection of Bugs, Drugs, and Special Populations.
Clinical pharmacology and therapeutics 04, 2021 | Pubmed ID: 33769563
Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes.
International journal of antimicrobial agents Jun, 2021 | Pubmed ID: 33785362
Antibiotic pharmacokinetic/pharmacodynamic modelling: MIC, pharmacodynamic indices and beyond.
International journal of antimicrobial agents Aug, 2021 | Pubmed ID: 34058336
Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis.
Frontiers in pharmacology , 2021 | Pubmed ID: 34408649
Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients.
CPT: pharmacometrics & systems pharmacology 12, 2021 | Pubmed ID: 34811968
Pharmacodynamic and immunomodulatory effects of polymyxin B in combination with fosfomycin against KPC-2-producing Klebsiella pneumoniae.
International journal of antimicrobial agents Apr, 2022 | Pubmed ID: 35288260
Knowledge dissemination and central indexing of resources in pharmacometrics: an ISOP education working group initiative.
Journal of pharmacokinetics and pharmacodynamics Aug, 2022 | Pubmed ID: 35474412
Clinical challenges treating infections: an update.
JAC-antimicrobial resistance Jun, 2022 | Pubmed ID: 35529051
Rajnikant Sharma1,
Shekhar Yeshwante1,
Quentin Vallé1,
Maytham Hussein2,
Varsha Thombare2,
Sean Michael McCann1,
Robert Maile3,4,5,
Jian Li6,
Tony Velkov2,
Gauri Rao1
1UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill,
2Department of Biochemistry & Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne,
3Department of Microbiology & Immunology, University of North Carolina School of Medicine,
4Department of Surgery, University of North Carolina at Chapel Hill,
5Curriculum in Toxicology and Environmental Medicine, University of North Carolina at Chapel Hill,
6Department of Microbiology, Monash Biomedicine Discovery Institute, Monash University
Sara Oberrauch1,
Jing Lu1,
Linda Cornthwaite-Duncan1,
Maytham Hussein1,
Jian Li2,
Gauri Rao3,
Tony Velkov1
1Department of Biochemistry & Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne,
2Department of Microbiology, Biomedicine Discovery Institute, Monash University,
3UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill
ACERCA DE JoVE
Copyright © 2024 MyJoVE Corporation. Todos los derechos reservados